SOUTH EASTON, Mass., April 28, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the inaugural Growth Capital Expo Investment Conference being held from April 29 to May 1, 2014 at Caesars Palace in Las Vegas, Nevada.

Mr. Schumacher is scheduled to present at 3:30 pm PDT on Wednesday April 30^th and again at 8:25 am PDT on Thursday May 1^st.  In addition to his two podium presentations, Mr. Schumacher (and the Company's Chairman Mr. Jeffrey N. Peterson) will also be available during the conference for one-on-one meetings with individual investors, investment funds, investment bankers, and other interested parties.  

About the Growth Capital Expo 2014 Investor Conference

Growth Capital Expo 2014 is the premier event in emerging growth company finance. Growth Capital Expo 2014 brings together the best ideas, the most promising companies, and the top deal makers in emerging growth finance for three days of education and networking in the nation's premier destination for meetings and entertainment.  Join 300 of the top growth company executives, investors, and finance specialists focused on the pre-IPO and public micro-cap market for an unparalleled experience in education, networking, and deal making.  More than forty emerging growth companies listed in the U.S., Canada, and other foreign exchanges are expected to present. For more information, please visit the conference website at www.growthcapitalexpo.com.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.      

For more information about PBI and this press release, please click on the following website link:
 http://www.pressurebiosciences.com 
Please Visit us on Facebook, LinkedIn, and Twitter

SOURCE Pressure BioSciences, Inc.